The deal adds to a rapidly-expanding pipeline of NASH candidates at Novo Nordisk, which also includes GLP-1 analogue semaglutide in ... ZyVersa is in the process of going public via a merger ...

Moreover, Novo Nordisk also claims that it is difficult to manufacture liraglutide and "even small changes in the manufacturing process of ... made a similar case for semaglutide in a petition ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

We came across a bullish thesis on Novo Nordisk A/S (NVO ... despite facing short-term headwinds in the U.S. from compounded semaglutide alternatives, is expected to rebound strongly through ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO ...

Novo Nordisk (NYSE:NVO) shares dropped 5% in early trading on Monday after Eli Lilly (NYSE:LLY) released new trial data showing its weight loss drug, Zepbound, delivered stronger results than Wegovy.

Is A Bottom Near? In a matter of just less than a year, not only has Novo Nordisk A/S (NVO) is assessed to have lost its leadership position in the U.S. weight loss drugs market to American ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders. The Danish pharmaceutical giant said the drug was more ...

Novo Nordisk has a strong economic moat based on significant market shares in diabetes and obesity care, and promising pipeline drugs, though facing competition and political pressures.

Novo Nordisk’s guidance is predicated on the idea that Wegovy and Ozempic will both benefit from a decrease in compounded semaglutide in the second half of the year. However, BofA’s analyst ...